-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Wndprusvx4umaoDbaZWgwiDKaGEyjyjSBH/vo1zDxWoqT+qqEfC4Zp4KW9IO3BpR tGv3HS8W1FZbRvvn2zHHTw== 0001144204-09-018095.txt : 20090401 0001144204-09-018095.hdr.sgml : 20090401 20090331190154 ACCESSION NUMBER: 0001144204-09-018095 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20081231 FILED AS OF DATE: 20090401 DATE AS OF CHANGE: 20090331 EFFECTIVENESS DATE: 20090401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORAGENICS INC CENTRAL INDEX KEY: 0001174940 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 593410522 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32188 FILM NUMBER: 09720933 BUSINESS ADDRESS: STREET 1: 12085 RESEARCH DRIVE CITY: ALACHUA STATE: FL ZIP: 32615 BUSINESS PHONE: 3864184018 MAIL ADDRESS: STREET 1: 12085 RESEARCH DRIVE CITY: ALACHUA STATE: FL ZIP: 32615 NT 10-K 1 v144985_nt-10k.htm Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 12b-25

NOTIFICATION OF LATE FILING



(Check One):

[ x ] Form 10-K   [    ] Form 20-F    [     ] Form 11-K
[    ] Form 10-Q   [    ] Form 10-D   [     ] Form N-SAR   [    ] Form N-CSR

For Period Ended:  December 31, 2008

[     ]         Transition Report on Form 10-K
[     ]         Transition Report on Form 20-F
[     ]         Transition Report on Form 11-K
[     ]         Transition Report on Form 10-Q
[     ]         Transition Report on Form N-SAR
 For the transition period ended: ______________________________
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
 



 
PART I
REGISTRANT INFORMATION

Full Name of Registrant: Oragenics, Inc.

Former Name if Applicable:  N/A

Address of Principal Executive Office (Street and Number):  13700 Progress Blvd.

City, State and Zip Code:  Alachua, Florida 32615


 
 

 

PART II
RULE 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate.)

 
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
[x]
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR, or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III
NARRATIVE

State below in reasonable detail the reasons why the Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

While the Company’s Form 10-K was completed by the time it was due to be filed it was unable to be timely converted for filing on the SEC’s edgar system prior to the filing deadline.  The Company expects its Form 10-K to be filed shortly after the filing deadline.

PART IV
OTHER INFORMATION

(1)           Name and telephone number of person to contact in regard to this notification
 
         
David Hirsch
   
(386) 418-4018
 
(Name)
   
(Area Code) (Telephone Number)
 
     
(2)           Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If answer is no, identify report(s).
 
[x] Yes  [   ] No

(3)           Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
[  ] Yes  [x] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 
- 2 - -

 


Oragenics, Inc.

(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

   
       
Date:   March 31, 2009
/s/ David Hirsch  
    By: Name   
    Title: Acting Chief Executive Officer  
       

 


 
- 3 - -

 

-----END PRIVACY-ENHANCED MESSAGE-----